A Phase II Study Of Preoperative Everolimus In Metastatic Renal Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms E-PREDICT
- 02 Oct 2012 Accrual to date is 17% according to United Kingdom Clinical Research Network.
- 19 Jun 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 18 Apr 2012 United Kingdom Clinical Research Network reports accrual date changed from 15% to 17%.